NLS Collaboration

A national COVID-19 biobank sample collection has been added to the COVID-19 Sample Collection Database, which is available through the Swedish Pandemic Preparedness Portal. This collection includes over 1.5 million samples that are available for use in research. The samples were collated as part of a collaboration between Swedish regional health agencies, the National Pandemic […]

On behalf of the Swedish government, the Swedish innovation agency Vinnova has decided on funding of an innovation cluster for commercialization, competence development and production capacity for advanced therapies. The new cluster will serve as a national infrastructure and competence node for the benefit of companies throughout the country and it will also strengthen Sweden’s […]

The two companies have announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advancing base editing capabilities, Novo Nordisk will leverage Life Edit’s suite of gene editing technologies to precisely edit the genome with the aim of developing life-changing therapies […]

Umeå based HiloProbe has entered a partnership with the major international company Biocartis Group. This is a strategically important step for HiloProbe in their aim to reach out globally with its colorectal cancer test-product, ColoNode, they state. “We are very happy to start a collaboration and a long-term relationship with Biocartis, which strengthens our focus […]

Salipro Biotech and DyNAbind have announced the achievement of a key milestone from their collaboration. The collaboration combines Salipro Biotech’s platform technology for membrane proteins with DyNAbind’s DNA-Encoded Library (DEL) technology to accelerate the development of novel drugs for challenging targets. Membrane proteins like GPCRs, SLC transporters and Ion Channels are an important but difficult-to-drug […]

Swedish Neogap and the Zurich-based company Cellerys has entered a collaboration related to Phase II study of a new therapy for multiple sclerosis. Cellerys will use Neogap’s patented EpiTCer technology in its upcoming Phase II study of a new type of cell therapy aimed at inducing antigen-specific immune tolerance in patients with multiple sclerosis (MS). […]